Dr Anthony Sedgwick
Dr. Anthony (Tony) Sedgwick is an experienced biotech executive, bringing over 40 years of international experience in the sector to Emergex. He was head of anti-inflammatory Biology at Roche between 1986-1990, and after a 2 year period in Marketing at Roche became Global head of Clinical operations until 2002.
At Roche, Tony was responsible for clinical development, leading to the launch of several products including Invirase® and Tamiflu® which have had significant impact both medically and commercially.
During his career, Tony has been the Chief Executive Officer of four biotechnology companies, Cambridge Biotechnology (2002-2005), DanioLabs (2005-2007), Novacta (2007-2011) and Silence Therapeutics (2011-2012), two of which successfully exited. He has also held Chairman positions at several companies including Plastid AS (2008-2011), ThioLogics (2011-2013) and most recently at Cotton Mouton Diagnostics (2017-2019).
During the past few years, Tony has specialised in ‘trusted’ advisor roles for CEOs and heads of R&D.
Tony holds a PhD in Experimental Pathology from St Bartholomew’s Hospital Medical School in London and is a Fellow of the Royal College of Pathologists and an honorary Professor at Swansea University Medical School.